CD4 and neoplasm: In most of these studies, patients presented a somewhat increased immunogenicity upon vaccination, including peptide-specific CD8+ T-cells [21,22,24,26,28,29,30,36,39,40], IFN-α production by injected DCs [20], tumor antigen-specific lymphoproliferative response [31], increased IFN-γ secreting cells [32,33,38], increased frequency of CD4+ CD25 high T cells [25], potent Th1 polarization [34,35], or delayed-type hypersensitivity (DTH) responses [29,33].